Synucleozid is primarily investigated for its potential in targeting alpha-synuclein, a protein implicated in neurodegenerative diseases such as Parkinson's disease. It works by reducing the aggregation of alpha-synuclein, which is a key pathological feature in these conditions. This makes it a promising candidate for therapeutic interventions aimed at slowing or halting disease progression. Researchers are exploring its efficacy in preclinical models to determine its safety and effectiveness, with the hope of developing it into a treatment that can improve outcomes for patients with Parkinson's and related disorders.